Pages that link to "Q37098302"
Jump to navigation
Jump to search
The following pages link to Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity (Q37098302):
Displaying 29 items.
- Quantitative characterization of in vitro bystander effect of antibody-drug conjugates (Q38817525) (← links)
- Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment (Q47103332) (← links)
- Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study (Q47644645) (← links)
- Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments (Q47851750) (← links)
- DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. (Q48177736) (← links)
- Drug conjugates—an emerging approach to treat breast cancer. (Q55438401) (← links)
- Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures (Q57073801) (← links)
- Progress and challenges in HER2-positive gastroesophageal adenocarcinoma (Q64052649) (← links)
- HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer (Q64063349) (← links)
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study (Q64109771) (← links)
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study (Q64109775) (← links)
- [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model (Q80110069) (← links)
- Yusuke Ogitani (Q80211783) (← links)
- Toshinori Agatsuma (Q80212579) (← links)
- HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates (Q89471865) (← links)
- Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance (Q89683058) (← links)
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study (Q89716965) (← links)
- Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond (Q89727324) (← links)
- Trastuzumab Deruxtecan: First Approval (Q90123033) (← links)
- Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer (Q90171453) (← links)
- Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models (Q90269095) (← links)
- Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond (Q90484961) (← links)
- A "Dual" Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC (Q91800684) (← links)
- Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer (Q91992316) (← links)
- Novel antibody-drug conjugates for triple negative breast cancer (Q95273167) (← links)
- Antibody-Drug Conjugates: The Last Decade (Q99555777) (← links)
- Antibody-drug conjugates: smart weapons against cancer (Q99630424) (← links)
- Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress (Q99708836) (← links)
- Local and systemic treatment for HER2-positive breast cancer with brain metastases: a comprehensive review (Q99711694) (← links)